Diğer Bağ Doku Hastalıklarında Nörolojik Tutulum
Özet
Bağ dokusu hastalıkları, otoimmün mekanizmalarla gelişen ve vücuttaki hemen hemen tüm organları etkileyebilen kronik süreçlerdir; nörolojik tutulum nadir görülse de hastaların yaşam kalitesini ve sağkalımını ciddi şekilde etkileyen kritik bir komplikasyondur. Çalışma, çocukluk çağındaki idiyopatik inflamatuar miyopatiler, mikst bağ doku hastalığı, juvenil sistemik skleroderma, lokalize skleroderma ve Sjögren sendromu gibi bağ dokusu hastalıklarında gelişebilecek nörolojik bulguları, vasküler ve inflamatuar patogenez temelinde detaylandırmaktadır. Bu hastalıkların tanı ve takibinde, spesifik klinik belirtilerin yanı sıra nörolojik semptomların da dikkatle değerlendirilmesi, uygun tedavi stratejilerinin belirlenmesi ve komplikasyonların önlenmesi açısından hayati öneme sahiptir.
Connective tissue diseases are chronic processes that develop through autoimmune mechanisms and can affect almost every organ in the body; although neurological involvement is rare, it is a critical complication that significantly impacts patient quality of life and survival. The study details potential neurological findings in childhood connective tissue diseases such as idiopathic inflammatory myopathies, mixed connective tissue disease, juvenile systemic sclerosis, localized scleroderma, and Sjögren's syndrome, based on vascular and inflammatory pathogenesis. In the diagnosis and follow-up of these diseases, careful evaluation of neurological symptoms alongside specific clinical manifestations is vital for determining appropriate treatment strategies and preventing complications.
Referanslar
Tepeli E, Ök N. Bağ Dokusu Hastalıkları. Turkiye Klinikleri J Med Genet-Special Topics. 2017;2(3):163-72
Peitz J, Tantcheva-Poór I. Kollagenosen bei Jugendlichen [Connective tissue diseases in adolescents]. Hautarzt. 2016;67(4):271-278
Lundberg IE, Tjärnlund A, Bottai M, et al. 2017 European League Against Rheumatism/American College of Rheumatology classification criteria for adult and juvenile idiopathic inflammatory myopathies and their major subgroups [published correction appears in Ann Rheum Dis. 2018 Sep;77(9):e64]. Ann Rheum Dis. 2017;76(12):1955-1964.
McCann LJ, Juggins AD, Maillard SM, et al. The Juvenile Dermatomyositis National Registry and Repository (UK and Ireland)--clinical characteristics of children recruited within the first 5 yr. Rheumatology (Oxford). 2006;45(10):1255-1260.
Symmons DP, Sills JA, Davis SM. The incidence of juvenile dermatomyositis: results from a nation-wide study. Br J Rheumatol. 1995;34(8):732-736.
Mendez EP, Lipton R, Ramsey-Goldman R, et al. US incidence of juvenile dermatomyositis, 1995-1998: results from the National Institute of Arthritis and Musculoskeletal and Skin Diseases Registry. Arthritis Rheum. 2003;49(3):300-305.
Pachman LM, Lipton R, Ramsey-Goldman R, et al. History of infection before the onset of juvenile dermatomyositis: results from the National Institute of Arthritis and Musculoskeletal and Skin Diseases Research Registry. Arthritis Rheum. 2005;53(2):166-172.
Barut K, Aydin POA, Adrovic A, Kasapçopur O. Juvenile dermatomyositis: a tertiary center experience. Clin Rheumatol, 2017; 36, 361–366
Pilkington CA,Feldman BM, Sontichai W.Juvenile Dermatomyositis and Other Inflammatory Muscle Diseases.Petty RE, Laxer RM, Lindsey CB, Wedderburn LR, Mellims ED, Fuhlbrigge RC, editorler. Textbook of Pediatric Rheumatology. 8. Baskı. Philadelphia: Elsevier;2021. p. 360-375.
Mamyrova G, O'Hanlon TP, Monroe JB, et al. Immunogenetic risk and protective factors for juvenile dermatomyositis in Caucasians. Arthritis Rheum. 2006;54(12):3979-3987.
Mamyrova G, O'Hanlon TP, Sillers L, et al. Cytokine gene polymorphisms as risk and severity factors for juvenile dermatomyositis. Arthritis Rheum. 2008;58(12):3941-3950.
Takaoka A, Yanai H. Interferon signalling network in innate defence. Cell Microbiol. 2006;8(6):907-922.
Feldman BM, Rider LG, Reed AM, Pachman LM. Juvenile dermatomyositis and other idiopathic inflammatory myopathies of childhood. Lancet. 2008;371(9631):2201-2212.
Nagaraju K, Casciola-Rosen L, Lundberg I, et al. Activation of the endoplasmic reticulum stress response in autoimmune myositis: potential role in muscle fiber damage and dysfunction. Arthritis Rheum. 2005;52(6):1824-1835.
Papadopoulou C, McCann LJ. The Vasculopathy of Juvenile Dermatomyositis. Front Pediatr. 2018;6:284.
Targoff IN, Miller FW, Medsger TA Jr, Oddis CV. Classification criteria for the idiopathic inflammatory myopathies. Curr Opin Rheumatol. 1997;9(6):527-535.
Bottai M, Tjärnlund A, Santoni G, et al. EULAR/ACR classification criteria for adult and juvenile idiopathic inflammatory myopathies and their major subgroups: a methodology report. RMD Open. 2017;3(2):e000507.
Bohan A, Peter JB. Polymyositis and dermatomyositis (first of two parts). N Engl J Med. 1975;292(7):344-347.
Guseinova D, Consolaro A, Trail L, et al. Comparison of clinical features and drug therapies among European and Latin American patients with juvenile dermatomyositis. Clin Exp Rheumatol. 2011 ve 29(1):117-124.
Robinson AB, Hoeltzel MF, Wahezi DM, et al. Clinical characteristics of children with juvenile dermatomyositis: the Childhood Arthritis and Rheumatology Research Alliance Registry. Arthritis Care Res (Hoboken). 2014;66(3):404-410.
Al-Mayouf SM, AlMutiari N, Muzaffer M, et al. Phenotypic characteristics and outcome of juvenile dermatomyositis in Arab children. Rheumatol Int. 2017;37(9):1513-1517.
Paganoni S, Amato A. Electrodiagnostic evaluation of myopathies. Phys Med Rehabil Clin N Am. 2013;24(1):193-207.
Brown VE, Pilkington CA, Feldman BM, Davidson JE; Network for Juvenile Dermatomyositis, Paediatric Rheumatology European Society (PReS). An international consensus survey of the diagnostic criteria for juvenile dermatomyositis (JDM). Rheumatology (Oxford). 2006;45(8):990-993.
Okong'o LO, Esser M, Wilmshurst J, Scott C. Characteristics and outcome of children with juvenile dermatomyositis in Cape Town: a cross-sectional study. Pediatr Rheumatol Online J. 2016;14(1):60.
Ramanan AV., Sawhney S, & Murray K J. (2001). Central nervous system complications in two cases of juvenile onset dermatomyositis. Rheumatology. 2001;40(11):1293–1298.
Bellutti Enders F, Bader-Meunier B, Baildam E, et al. Consensus-based recommendations for the management of juvenile dermatomyositis. Ann Rheum Dis. 2017;76(2):329-340.
Shah M, Mamyrova G, Targoff IN, et al. The clinical phenotypes of the juvenile idiopathic inflammatory myopathies. Medicine (Baltimore). 2013;92(1):25-41.
Mamyrova G, Katz JD, Jones RV, et al. Clinical and laboratory features distinguishing juvenile polymyositis and muscular dystrophy. Arthritis Care Res (Hoboken). 2013;65(12):1969-1975.
Vattemi G, Mirabella M, Guglielmi V, et al. Muscle biopsy features of idiopathic inflammatory myopathies and differential diagnosis. Auto Immun Highlights. 2014;5(3):77-85.
Senator H. Ueber acute polymyositis und neuromyositis. Deutsche Med Wochenschrift 1893;19:933-6.
Park, C. K., Yoo, S.-J., Yoo, at al. Neuromyositis: A Rare Extramuscular Manifestation of Dermatomyositis. J Rheum Dis 2019;26:211-218.
Onder H, GökcemYıldız F, Temucin ÇM. Neuromyositis: clinical and electrophysiological study of 8 cases. Global Adv Res J Med Med Sci 2015;4:347-50.
Cojocaru IM, Socoliuc G, Sapira V, Bastian A, Alexianu M, Moldovan M. Dermatomyositis and polyradiculoneuritis, a rare association. Rom J Intern Med 2011;49:217-21.
Nguyen TP, Bangert C, Biliciler S, Athar P, Sheikh K. Dermatomyositis-associated sensory neuropathy: a unifying pathogenic hypothesis. J Clin Neuromuscul Dis. 2014;16(1):7-11.
Nomura M, Watanabe T, Mikami H, et al. Adult dermatomyositis with severe polyneuropathy: does neuromyositis exist?. Neurol Sci. 2010;31(3):373-376.
Vogelgesang SA, Gutierrez J, Klipple GL, Katona IM. Polyneuropathy in juvenile dermatomyositis. J Rheumatol. 1995;22(7):1369-1372.
Irie T, Shigeto H, Koge J, Yamaguchi H, Murai H, Kira JI. Dermatomyositis complicated with asymmetric peripheral neuritis on exacerbation: a case report and literature review. Clin Exp Neuroimmunol 2016; 7:373-80.
da Costa IP, Pradebon EP, Campos JV, Melo FS, Tavares FM. Polymyositis associated with lymphocytic arteritis of the central nervous system. Rev Bras Reumatol. 2010;50(1):90-95.
Sharp GC, Irvin WS, Tan EM, Gould RG, Holman HR. Mixed connective tissue disease--an apparently distinct rheumatic disease syndrome associated with a specific antibody to an extractable nuclear antigen (ENA). Am J Med. 1972;52(2):148-159.
Lundberg IE. The prognosis of mixed connective tissue disease. Rheum Dis Clin North Am. 2005;31(3):535-47.
Makay B. Mikst Bağ Doku Hastalığı. Poyrazoğlu MH, Sözeri B, editörler. Çocuk Romatoloji Kitabı. 1. Baskı. Ankara: Güneş Tıp Kitapevi; 2018. p.187-191.
Johnson JC, Sharp GC. Long-term outcome in mixed connective tissue disease. Arthritis Rheum. 1999; 2:899–909.
Mier RJ, Shishov M, Higgins GC, et al. Pediatric-onset mixed connective tissue disease. Rheum Dis Clin North Am. 2005;31(3):483-496.
Tsai YY, Yang YH, Yu HH, Wang LC, Lee JH, Chiang BL. Fifteen-year experience of pediatric-onset mixed connective tissue disease. Clin Rheumatol. 2010;29(1):53-58.
Flåm ST, Gunnarsson R, Garen T; Norwegian MCTD Study Group, Lie BA, Molberg Ø. The HLA profiles of mixed connective tissue disease differ distinctly from the profiles of clinically related connective tissue diseases. Rheumatology (Oxford). 2015;54(3):528-535.
Berard RA, Laxer RM. Pediatric Mixed Connective Tissue Disease. Curr Rheumatol Rep. 2016;18(5):28.
Tellier S, Bader-Meunier B, Quartier P, et al. Initial presentation and outcome of pediatric-onset mixed connective tissue disease: A French multicenter retrospective study. Joint Bone Spine. 2016;83(3):369-371.
van der Net J, van der Hoeven H, Esseveld F, de Wilde EJ, Kuis W, Helders PJ. Musculoskeletal disorders in juvenile onset mixed connective tissue disease. J Rheumatol. 1995;22(4):751-757.
Bennett RM, Bong DM, Spargo BH. Neuropsychiatric problems in mixed connective tissue disease. Am J Med. 1978;65(6):955-962.
Burdt MA, Hoffman RW, Deutscher SL, Wang GS, Johnson JC, Sharp GC. Long-term outcome in mixed connective tissue disease: longitudinal clinical and serologic findings. Arthritis Rheum. 1999;42(5):899-909.
Hojaili B, Barland P. Trigeminal neuralgia as the first manifestation of mixed connective tissue disorder. J Clin Rheumatol. 2006;12(3):145-147.
Hämeenkorpi R, Ruuska P, Forsberg S, Tiilikainen R, Mäkitalo R, Hakala M. More evidence of distinctive features of mixed connective tissue disease. Scand J Rheumatol. 1993;22(2):63-68.
Debette S, Germain DP. Neurologic manifestations of inherited disorders of connective tissue. Handb Clin Neurol. 2014;119:565-576.
Nadeau SE. Neurologic manifestations of connective tissue disease. Neurol Clin. 2002;20(1):151-178.
Rayes HA, Al-Sheikh A, Al Dalaan A, Al Saleh S. Mixed connective tissue disease: the King Faisal Specialist Hospital experience. Ann Saudi Med. 2002;22(1-2):43-46.
Karmacharya P, Mainali NR, Aryal MR, Lloyd B. Recurrent case of ibuprofen-induced aseptic meningitis in mixed connective tissue disease. BMJ Case Rep. 2013;2013:bcr2013009571.
Sato T, Fujii T, Yokoyama T, et al. Anti-U1 RNP antibodies in cerebrospinal fluid are associated with central neuropsychiatric manifestations in systemic lupus erythematosus and mixed connective tissue disease. Arthritis Rheum. 2010;62(12):3730-3740.
Shah PM, Dhakre VW, Bhabhor A, Prasad A. Superior sagittal sinus thrombosis in a case of Mixed Connective Tissue Disease. BMJ Case Rep. 2018;2018:bcr2018225078.
Kim ST, Brinjikji W, Lanzino G, Kallmes DF. Neurovascular manifestations of connective-tissue diseases: A review. Interv Neuroradiol. 2016;22(6):624-637.
Matsui H, Udaka F, Oda M, Kubori T, Nishinaka K, Kameyama M. Encephalopathy and severe neuropathy due to probable systemic vasculitis as an initial manifestation of mixed connective tissue disease. Neurol India. 2006;54(1):83-85.
Leibfarth JH, Persellin RH. Characteristics of patients with serum antibodies to extractable nuclear antigens. Arthritis Rheum. 1976;19(5):851-856.
Hajas A, Szodoray P, Barath S, et al. Sensorineural hearing loss in patients with mixed connective tissue disease: immunological markers and cytokine levels. J Rheumatol. 2009;36(9):1930-1936.
Kiani IG, Qureshi SH, Shah F. Depression and seizures as the main neuropsychiatric manifestation of mixed connective tissue disorder. J Coll Physicians Surg Pak. 2014;24 Suppl 2:S141-S143.
Manohar H, Kuppili PP, Menon V. Major depression: An under reported neuropsychiatric manifestation of Mixed Connective Tissue Disease. Asian J Psychiatr. 2017;30:54-55.
Nowicka-Sauer K, Czuszynska Z, Majkowicz M, et al. Neuropsychological assessment in mixed connective tissue disease: comparison with systemic lupus erythematosus. Lupus. 2012;21(9):927-933.
Habets WJ, de Rooij DJ, Salden MH, et al. Antibodies against distinct nuclear matrix proteins are characteristic for mixed connective tissue disease. Clin Exp Immunol. 1983;54(1):265-276.
Laffon-Pioger M, Rocher F, Cohen M, Chanalet S, Thomas P, Lebrun C. Névrite optique rétrobulbaire bilatérale cécitante après vaccination contre la grippe saisonnière chez une patiente présentant un syndrome de Sharp [Bilateral optic neuropathy with loss of vision after an influenza vaccination in a patient suffering from mixed connective tissue disease]. Rev Neurol (Paris). 2010;166(12):1024-1027.
Flechtner K, Baum K. Mixed connective tissue disease: recurrent episodes of optic neuropathy and transverse myelopathy. Successful treatment with plasmapheresis. J Neurol. 1994; 126(2):146-148
Bhinder S, Harbour K, Majithia V. Transverse myelitis, a rare neurological manifestation of mixed connective tissue disease--a case report and a review of literature. Clin Rheumatol. 2007;26(3):445-447.
Hao Y, Feng L, Teng Y, Cheng Y, Feng J. Management of multiple neurological complications in mixed connective tissue disease: A case report. Medicine (Baltimore). 2018;97(31):e11360.
Weatherby SJ, Davies MB, Hawkins CP, Haq N, Dawes P. Transverse myelopathy, a rare complication of mixed connective tissue disease: comparison with SLE related transverse myelopathy. J Neurol Neurosurg Psychiatry. 2000;68(4):532-533.
Schedel J, Kuchenbuch S, Schoelmerich J, Feuerbach S, Geissler A, Mueller-Ladner U. Cerebral lesions in patients with connective tissue diseases and systemic vasculitides: are there specific patterns?. Ann N Y Acad Sci. 2010;1193:167-175.
Hetlevik SO, Flatø B, Rygg M, et al. Long-term outcome in juvenile-onset mixed connective tissue disease: a nationwide Norwegian study. Ann Rheum Dis. 2017;76(1):159-165.
Rahmanzadeh R, Rahmanzade R, Zabihiyeganeh M. Posterior reversible encephalopathy syndrome in a patient with mixed connective tissue disease: a case report. J Med Case Rep. 2016;10(1):145.
Hao Y, Xin M, Wang S, Ma D, Feng J. Myelopathy associated with mixed connective tissue disease: clinical manifestation, diagnosis, treatment, and prognosis. Neurol Sci. 2019;40(9):1785-1797.
Kotajima L, Aotsuka S, Sumiya M, Yokohari R, Tojo T, Kasukawa R. Clinical features of patients with juvenile onset mixed connective tissue disease: analysis of data collected in a nationwide collaborative study in Japan. J Rheumatol. 1996;23(6):1088-1094.
Rongioletti F, Ferreli C, Atzori L, Bottoni U, Soda G. Scleroderma with an update about clinico-pathological correlation. G Ital Dermatol Venereol. 2018;153(2):208-215.
Zulian F, Vallongo C, Woo P, et al. Localized scleroderma in childhood is not just a skin disease. Arthritis Rheum. 2005;52(9):2873-2881.
Herrick AL, Ennis H, Bhushan M, Silman AJ, Baildam EM. Incidence of childhood linear scleroderma and systemic sclerosis in the UK and Ireland. Arthritis Care Res (Hoboken). 2010;62(2):213-218.
Beukelman T, Xie F, Foeldvari I. Assessing the prevalence of juvenile systemic sclerosis in childhood using administrative claims data from the United States. Journal of Scleroderma and Related Disorders. 2018; 3(2):189-190.
Pelkonen PM, Jalanko HJ, Lantto RK, et al. Incidence of systemic connective tissue diseases in children: a nationwide prospective study in Finland. J Rheumatol. 1994;21(11):2143-2146.
Stevens BE, Torok KS, Li SC, et al. Clinical Characteristics and Factors Associated With Disability and Impaired Quality of Life in Children With Juvenile Systemic Sclerosis: Results From the Childhood Arthritis and Rheumatology Research Alliance Legacy Registry. Arthritis Care Res (Hoboken). 2018;70(12):1806-1813.
Scalapino K, Arkachaisri T, Lucas M, et al. Childhood onset systemic sclerosis: classification, clinical and serologic features, and survival in comparison with adult onset disease. J Rheumatol. 2006;33(5):1004-1013.
Martini G, Foeldvari I, Russo R, et al. Systemic sclerosis in childhood: clinical and immunologic features of 153 patients in an international database. Arthritis Rheum. 2006;54(12):3971-3978.
Stevens AM, Torok KS, Li SC, Taber SF, Lu TT, Zulian F. Immunopathogenesis of Juvenile Systemic Sclerosis. Front Immunol. 2019;10:1352.
Medsger TA Jr. Assessment of damage and activity in systemic sclerosis. Curr Opin Rheumatol. 2000;12(6):545-548.
Torok KS, Stevens AM. Juvenile Systemic Sclerosis. Petty RE, Laxer RM, Lindsey CB, Wedderburn LR, Mellims ED, Fuhlbrigge RC, editors. Textbook of Pediatric Rheumatology. 8. Baskı. Philadelphia: Elsevier ;2021. p. 377-401
Bielsa Marsol I. Update on the classification and treatment of localized scleroderma. Actas Dermosifiliogr. 2013; 104(8):654-666.
Laxer RM, Zulian F. Localized scleroderma. Curr Opin Rheumatol. 2006;18(6):606-613.
Zulian F, Culpo R, Sperotto F, et al.Consensus-based recommendations for the management of juvenile localised scleroderma.Annals of the Rheumatic Diseases 2019; 78:1019-1024.
Zulian F, Tirelli F. Treatment in Juvenile Scleroderma. Curr Rheumatol Rep. 2020;22(8):45.
Christen-Zaech S, Hakim MD, Afsar FS, Paller AS. Pediatric morphea (localized scleroderma): review of 136 patients. J Am Acad Dermatol. 2008;59(3):385-396.
Kreuter A, Mitrakos G, Hofmann SC, et al. Localized Scleroderma of the Head and Face Area: A Retrospective Cross-sectional Study of 96 Patients from 5 German Tertiary Referral Centres. Acta Derm Venereol. 2018;98(6):603-605.
De Somer L, Morren MA, Muller PC, et al. Overlap between linear scleroderma, progressive facial hemiatrophy and immune-inflammatory encephalitis in a paediatric cohort. Eur J Pediatr. 2015;174(9):1247-1254.
Kister I, Inglese M, Laxer RM, Herbert J. Neurologic manifestations of localized scleroderma: a case report and literature review. Neurology. 2008;71(19):1538-1545.
Amaral TN, Marques Neto JF, Lapa AT, Peres FA, Guirau CR, Appenzeller S. Neurologic involvement in scleroderma en coup de sabre. Autoimmune Dis. 2012;2012:719685.
Flores-Alvarado DE, Esquivel-Valerio JA, Garza-Elizondo M, Espinoza LR. Linear scleroderma en coup de sabre and brain calcification: is there a pathogenic relationship?. J Rheumatol. 2003;30(1):193-195.
Amaral TN, Peres FA, Lapa AT, Marques-Neto JF, Appenzeller S. Neurologic involvement in scleroderma: a systematic review. Semin Arthritis Rheum. 2013;43(3):335-347.
Chiu YE, Vora S, Kwon EK, Maheshwari M. A significant proportion of children with morphea en coup de sabre and Parry-Romberg syndrome have neuroimaging findings. Pediatr Dermatol. 2012;29(6):738-748.
Kraus V, Lawson EF, von Scheven E, et al. Atypical cases of scleroderma en coup de sabre. J Child Neurol. 2014;29(5):698-703.
Tucker L, Cozianna C. Sjögren Syndrome and Immunglobulin-G4 Disease. Petty RE, Laxer RM, Lindsey CB, Wedderburn LR, Mellims ED, Fuhlbrigge RC, editors. Textbook of Pediatric Rheumatology. 8. Baskı.Philadelphia: Elsevier;2021. p. 417–426.
Brito-Zerón P, Baldini C, Bootsma H, et al. Sjögren syndrome. Nat Rev Dis Primers. 2016;2:16047. Published 2016 Jul 7.
Binard A, Devauchelle-Pensec V, Fautrel B, Jousse S, Youinou P, Saraux A. Epidemiology of Sjögren's syndrome: where are we now?.Clin Exp Rheumatol. 2007;25(1):1-4.
Means C, Aldape MA, King E. Pediatric primary Sjögren syndrome presenting with bilateral ranulas: A case report and systematic review of the literature. Int J Pediatr Otorhinolaryngol. 2017;101:11-19.
Yokogawa N, Lieberman SM, Sherry DD, Vivino FB. Features of childhood Sjögren's syndrome in comparison to adult Sjögren's syndrome: considerations in establishing child-specific diagnostic criteria. Clin Exp Rheumatol. 2016;34(2):343-351.
Zhao J, Chen Q, Zhu Y, et al. Nephrological disorders and neurological involvement in pediatric primary Sjogren syndrome:a case report and review of literature. Pediatr Rheumatol Online J. 2020;18(1):39.
Goules AV, Tzioufas AG, Moutsopoulos HM. Classification criteria of Sjögren's syndrome. J Autoimmun. 2014;48-49:42-45.
Leone MC, Alunno A, Cafaro G, et al. The clinical spectrum of primary Sjögren's syndrome: beyond exocrine glands. Reumatismo. 2017;69(3):93-100.
Vivino FB, Bunya VY, Massaro-Giordano G, et al. Sjogren's syndrome: An update on disease pathogenesis, clinical manifestations and treatment. Clin Immunol. 2019;203:81-121.
McCoy SS, Baer AN. Neurological Complications of Sjögren's Syndrome: Diagnosis and Management. Curr Treatm Opt Rheumatol. 2017;3(4):275-288.
Kumon K, Satake A, Mizumoto M, Kobayashi I, Ishikawa N. A case of sensory neuropathy associated with childhood Sjögren syndrome. Eur J Pediatr. 2000;159(8):630-631.
Rojas-Rodriguez J, Garcia-Carrasco M, Ramirez ES, et al. Optic neuropathy in a child with primary Sjögren's syndrome. Rev Rhum Engl Ed. 1998;65(5):355-357.
Kobayashi I, Furuta H, Tame A, et al. Complications of childhood Sjögren syndrome. Eur J Pediatr. 1996;155(10):890-894.
Gottfried JA, Finkel TH, Hunter JV, Carpentieri DF, Finkel RS. Central nervous system Sjögren's syndrome in a child: case report and review of the literature. J Child Neurol. 2001;16(9):683-685.
Gmuca S, Lieberman SM, Mehta J. Pediatric Neuromyelitis Optica Spectrum Disorder and Sjögren Syndrome: More Common Than Previously Thought?. J Rheumatol. 2017;44(6):959-960.
Kornitzer JM, Kimura Y, Janow GL. Primary Sjögren Syndrome in a Child with a Neuromyelitis Optica Spectrum Disorder. J Rheumatol. 2016;43(6):1260-1261.
Massara A, Bonazza S, Castellino G, et al. Central nervous system involvement in Sjögren's syndrome: unusual, but not unremarkable--clinical, serological characteristics and outcomes in a large cohort of Italian patients. Rheumatology (Oxford). 2010;49(8):1540-1549.
